Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 472

1.

Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom Macroglobulinemia.

Li N, Lopez MA, Linares M, Kumar S, Oliva S, Martinez-Lopez J, Xu L, Xu Y, Perini T, Senapedis W, Baloglu E, Shammas MA, Hunter ZR, Anderson KC, Treon SP, Munshi NC, Fulciniti M.

Clin Cancer Res. 2018 Sep 11. pii: clincanres.1776.2018. doi: 10.1158/1078-0432.CCR-18-1776. [Epub ahead of print]

PMID:
30206161
2.

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.

Lopez-Anglada L, Cueto-Felgueroso C, Rosiñol L, Oriol A, Teruel AI, Lopez de la Guia A, Bengoechea E, Palomera L, de Arriba F, Hernandez JM, Granell M, Peñalver FJ, Garcia-Sanz R, Besalduch J, Gonzalez Y, Martinez RB, Hernandez MT, Gutierrez NC, Puerta P, Valeri A, Paiva B, Blade J, Mateos MV, San Miguel J, Lahuerta JJ, Martinez-Lopez J; GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group.

PLoS One. 2018 Sep 7;13(9):e0203392. doi: 10.1371/journal.pone.0203392. eCollection 2018.

3.

Clinical utility of ICD-11 diagnostic guidelines for high-burden mental disorders: results from mental health settings in 13 countries.

Reed GM, Keeley JW, Rebello TJ, First MB, Gureje O, Ayuso-Mateos JL, Kanba S, Khoury B, Kogan CS, Krasnov VN, Maj M, de Jesus Mari J, Sharan P, Stein DJ, Zhao M, Akiyama T, Andrews HF, Asevedo E, Cheour M, Domínguez-Martínez T, El-Khoury J, Fiorillo A, Grenier J, Gupta N, Kola L, Kulygina M, Leal-Leturia I, Luciano M, Lusu B, Martínez-López JNI, Matsumoto C, Odunleye M, Onofa LU, Paterniti S, Purnima S, Robles R, Sahu MK, Sibeko G, Zhong N, Gaebel W, Lovell AM, Maruta T, Pike KM, Roberts MC, Medina-Mora ME.

World Psychiatry. 2018 Oct;17(3):306-315. doi: 10.1002/wps.20581.

4.

Correction: Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.

Cedena MT, Rapado I, Santos-Lozano A, Ayala R, Onecha E, Abaigar M, Such E, Ramos F, Cervera J, Díez-Campelo M, Sanz G, Rivas JH, Lucía A, Martínez-López J.

Oncotarget. 2018 Jul 20;9(56):30936. doi: 10.18632/oncotarget.25856. eCollection 2018 Jul 20.

5.

Novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.

Onecha E, Linares M, Rapado I, Ruiz-Heredia Y, Martinez-Sanchez P, Cedena T, Pratcorona M, Perez Oteyza J, Herrera P, Barragan E, Montesinos P, Garcia Vela JA, Magro E, Anguita E, Figuera A, Riaza R, Martinez-Barranco P, Sanchez-Vega B, Nomdedeu J, Gallardo M, Martinez-Lopez J, Ayala R.

Haematologica. 2018 Aug 9. pii: haematol.2018.194712. doi: 10.3324/haematol.2018.194712. [Epub ahead of print]

6.

Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.

Macauda A, Castelli E, Buda G, Pelosini M, Butrym A, Watek M, Kruszewski M, Vangsted AJ, Rymko M, Jamroziak K, Abildgaard N, Haastrup EK, Mazur G, Ríos R, Jurczyszyn A, Zawirska D, Dudziński M, Raźny M, Dutka M, Tomczak W, Suska A, Druzd-Sitek A, Marques H, Petrini M, Markiewicz M, Martinez-Lopez J, Ebbesen LH, Iskierka-Jażdżewska E, Sainz J, Canzian F, Campa D.

Br J Haematol. 2018 Aug 6. doi: 10.1111/bjh.15521. [Epub ahead of print]

PMID:
30079960
7.

Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia.

Genescà E, Lazarenkov A, Morgades M, Berbis G, Ruíz-Xivillé N, Gómez-Marzo P, Ribera J, Juncà J, González-Pérez A, Mercadal S, Guardia R, Artola MT, Moreno MJ, Martínez-López J, Zamora L, Barba P, Gil C, Tormo M, Cladera A, Novo A, Pratcorona M, Nomdedeu J, González-Campos J, Almeida M, Cervera J, Montesinos P, Batlle M, Vives S, Esteve J, Feliu E, Solé F, Orfao A, Ribera JM.

J Hematol Oncol. 2018 Jul 24;11(1):96. doi: 10.1186/s13045-018-0639-8.

8.

Spectrum and functional validation of PSMB5 mutations in multiple myeloma.

Barrio S, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Leich E, Chatterjee M, Driessen C, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou RC, Braggio E, Stewart AK, Raab MS, Einsele H, Kortüm KM.

Leukemia. 2018 Jul 19. doi: 10.1038/s41375-018-0216-8. [Epub ahead of print]

PMID:
30026573
9.

Free satellite data key to conservation.

Buchanan GM, Beresford AE, Hebblewhite M, Escobedo FJ, De Klerk HM, Donald PF, Escribano P, Koh LP, Martínez-López J, Pettorelli N, Skidmore AK, Szantoi Z, Tabor K, Wegmann M, Wich S.

Science. 2018 Jul 13;361(6398):139-140. doi: 10.1126/science.aau2650. No abstract available.

PMID:
30002246
10.

Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.

Ruiz-Heredia Y, Sànchez-Vega B, Onecha E, Barrio S, Alonso R, Martínez-Ávila JC, Cuenca I, Agirre X, Braggio E, Hernández MT, Martínez R, Rosiñol L, Gutierrez N, Martin-Ramos M, Ocio EM, Echeveste MA, Pérez de Oteyza J, Oriol A, Bargay J, Gironella M, Ayala R, Bladé J, Mateos MV, Kortum KM, Stewart K, García-Sanz R, San Miguel J, Lahuerta JJ, Martinez-Lopez J.

Haematologica. 2018 Jun 28. pii: haematol.2018.188839. doi: 10.3324/haematol.2018.188839. [Epub ahead of print]

11.

A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.

Primo D, Scarfò L, Xochelli A, Mattsson M, Ranghetti P, Espinosa AB, Robles A, Gorrochategui J, Martínez-López J, de la Serna J, González M, Gil AC, Anguita E, Iraheta S, Munugalavadla V, Quéva C, Tannheimer S, Rosenquist R, Stamatopoulos K, Ballesteros J, Ghia P.

Oncotarget. 2018 May 25;9(40):26019-26031. doi: 10.18632/oncotarget.25419. eCollection 2018 May 25.

12.

Prognostic factors and predictive model for in-hospital mortality following hip fractures in the elderly.

Sanz-Reig J, Salvador Marín J, Ferrández Martínez J, Orozco Beltrán D, Martínez López JF, Quesada Rico JA.

Chin J Traumatol. 2018 Jun;21(3):163-169. doi: 10.1016/j.cjtee.2017.10.006. Epub 2018 Apr 25.

13.

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators.

Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4.

PMID:
29735299
14.

Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report.

Ruiz-Heredia Y, Sanchez-Vega B, Barrio S, Linares M, Rapado I, Braggio E, Stewart K, Folgueira MD, Ramos A, Collado L, Ruiz J, Toldos O, Hernandez-Lain A, Martinez-Lopez J.

J Oncol Pharm Pract. 2018 Jan 1:1078155218769367. doi: 10.1177/1078155218769367. [Epub ahead of print]

PMID:
29690814
15.

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.

Misiewicz-Krzeminska I, Corchete LA, Rojas EA, Martínez-López J, García-Sanz R, Oriol A, Bladé J, Lahuerta JJ, Miguel JS, Mateos MV, Gutiérrez NC.

Haematologica. 2018 May;103(5):880-889. doi: 10.3324/haematol.2017.181628. Epub 2018 Mar 15.

16.

How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?

Fernández L, Leivas A, Valentín J, Escudero A, Corral D, de Paz R, Vela M, Bueno D, Rodríguez R, Torres JM, Díaz-Almirón M, López-Collazo E, Martinez-Lopez J, Pérez-Martínez A.

Transfusion. 2018 Jun;58(6):1340-1347. doi: 10.1111/trf.14573. Epub 2018 Mar 14.

PMID:
29542132
17.

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, San Miguel JF.

Leukemia. 2018 Feb 23. doi: 10.1038/s41375-018-0072-6. [Epub ahead of print]

PMID:
29515235
18.

Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.

Vela M, Corral D, Carrasco P, Fernández L, Valentín J, González B, Escudero A, Balas A, de Paz R, Torres J, Leivas A, Martinez-Lopez J, Pérez-Martínez A.

Cancer Lett. 2018 May 28;422:107-117. doi: 10.1016/j.canlet.2018.02.033. Epub 2018 Feb 23.

PMID:
29477379
19.

Prognostic risk models for transplant decision-making in myelofibrosis.

Hernández-Boluda JC, Pereira A, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Gómez M, Cervantes F.

Ann Hematol. 2018 May;97(5):813-820. doi: 10.1007/s00277-018-3240-x. Epub 2018 Jan 25.

PMID:
29396714
20.

Papain-treated panels are a simple method for the identification of alloantibodies in multiple myeloma patients treated with anti-CD38-based therapies.

Carreño-Tarragona G, Cedena T, Montejano L, Alonso R, Miras F, Valeri A, Rivero A, Lahuerta JJ, Martinez-Lopez J.

Transfus Med. 2018 Jan 25. doi: 10.1111/tme.12508. [Epub ahead of print]

PMID:
29369430

Supplemental Content

Loading ...
Support Center